← Back to headlines
AbbVie Lowers Q1 and FY 2026 Earnings Outlook After R&D Charge
AbbVie has revised down its earnings outlook for the first quarter and full fiscal year 2026, following a significant $744 million research and development charge.
6 Apr, 11:18 — 6 Apr, 11:18
Sources
Showing 1 of 1 sources
Related Stories
Honda Orders $9 Billion Supplier Cost Cuts to Counter Chinese EV Rivals
19m ago
US-Iran Military Clashes Intensify, Rattling Global Markets and Energy Prices
22m ago
Apple Appoints John Ternus as CEO Amid Leadership Transition and Strategic Shift
24m ago
Nestlé to Sell Vitamins Business to Financial Investor for $1 Billion
39m ago